<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DE77CDB3-E451-40FC-A35D-F2CCFC4C984C"><gtr:id>DE77CDB3-E451-40FC-A35D-F2CCFC4C984C</gtr:id><gtr:firstName>Quentin</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Sattentau</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4CD2AF42-0F0D-4694-A7DF-16C5991E502F"><gtr:id>4CD2AF42-0F0D-4694-A7DF-16C5991E502F</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0000635"><gtr:id>23475BA5-94FF-4087-8FA6-3D1E2811D194</gtr:id><gtr:title>Optimising immunogenicity of the HIV-1 envelope glycoproteins for vaccine use</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000635</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1006435</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine and Biomedical Sciences</gtr:department><gtr:description>The Bill and Melina Gates Grand Challenges for Glocal Health</gtr:description><gtr:id>E26FB8CA-1A5A-45C3-B421-32E6D3F9C05F</gtr:id><gtr:impact>The initiation of two clinical trials with their design partly based upon our animal model data</gtr:impact><gtr:partnerContribution>we have integrated into a network of groups interested in mucosal immunity against HIV-1. This has allowed us to share and acquire information and results that would otherwise have been impossible, and make significant advances towards vaccine design.</gtr:partnerContribution><gtr:piContribution>We are responsible for developing mouse and rabbit models of vaginal immunisation with HIV-1 antigens and with mucosal adjuvants.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Centre for Virology (Bloomsbury)</gtr:department><gtr:description>The Global HIV Vaccine Enterprise Collaboration for AIDS Vaccine Discovery</gtr:description><gtr:id>07FC44FD-A56A-45A8-8049-FB03DFB8C73C</gtr:id><gtr:impact>We have produced a panel of new monoclonal antibodies with neutralising activity against HIV-1 that will be used as templates for vaccine antigen design. We have begun to design and develop new vaccine antigens.</gtr:impact><gtr:partnerContribution>We have together established a large consortium in which I ama deputy PI, which is focussed on HIV vaccine design and development.</gtr:partnerContribution><gtr:piContribution>We have formed a collaborative network of groups that interact to design and develop antigens to elicit neutralising antibodies against HIV-1.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>The International AIDS Vaccine Initiative Neutralising antibody consortium</gtr:description><gtr:id>9DCF2384-05DB-43B8-AA29-C4CACBB3AEDC</gtr:id><gtr:impact>several experimental animal immunogenicity studies have been carried out</gtr:impact><gtr:partnerContribution>This consortium has provided a network of groups focused on designing and developing a vaccine antigen for eliciting neutralising antibodies to HIV-1. In this consortium we share reagents, resources, ideas and results.</gtr:partnerContribution><gtr:piContribution>We have participated in characterisation of the HIV-1 viral envelope glycoprotein spike so as to understand the relationship between structure and function in terms of antibody neutralisation. We are participating in new antigen design strategies.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Editorial in Public service Magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D26737C2-702D-4314-807E-D8A722D4C729</gtr:id><gtr:impact>I write an editorial for the magazine Public Service Review UK Science and Technology, on the importance of supporting basic research in order to maintain the future pipeline of new ideas and technologies.

I have had several requests for further information from interested parties who read the article.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>In a nutshell</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ACC3A305-9445-4EA3-B301-034F6B58A845</gtr:id><gtr:impact>A presentation to the general public and to schoolchildren on our work trying to develop vaccines against HIV

lots of questions!</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Public Service magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B1CBB781-6023-4BB0-9125-179CC1738DE7</gtr:id><gtr:impact>The article I wrote described in lay terms the current efforts in designing a preventative vaccine for HIV/AIDS and was published in the international magazine Public Service Review, UK Science and Technology.

I have had several requests for further information from interested parties who read the article.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>351146</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Collaboration for AIDS Vaccine Discovery</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>R35094</gtr:fundingRef><gtr:id>FA467BE7-01C1-497E-9C25-78056DBDE92B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>351146</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>The Bill and Melinda Gates Foundation project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1113647</gtr:fundingRef><gtr:id>BD694840-13EC-4E90-82DB-5097344C7A5F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>523923</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaboration for AIDS Vaccine Discovery</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>3C60F0EA-543F-40CD-BA33-07FE44CF471E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>368417</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC responsive mode funding</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N005821/1</gtr:fundingRef><gtr:id>77069A59-580F-42D0-90AE-9B258B03C130</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission EHVA H2020</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>681032</gtr:fundingRef><gtr:id>D637C4B2-BB3B-4A80-AD3B-DE67BF1F59C7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission EAVI H2020</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>681137</gtr:fundingRef><gtr:id>B20FF2F3-1851-4762-90A3-BDD7BDEF32ED</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neutralizing antibody consortium</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>International AIDS Vaccine Initiative (IAVI)</gtr:fundingOrg><gtr:id>E9D5B78D-52F8-4B4B-ACB8-20F6EAB6164C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>89229</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Modular research proposal Adjuplex - modules 1 &amp;amp; 2</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Advanced BioAdjuvants</gtr:fundingOrg><gtr:id>DA17D022-8889-495C-B7A6-D7E53053820B</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concepts</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC-PC-12020</gtr:fundingRef><gtr:id>3138274B-74AF-4BBD-A0AC-2BF5AFEC4B64</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>233825</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Standard</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M026302/1</gtr:fundingRef><gtr:id>27871FAF-2BDE-4726-A852-9744C211D3E0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>245083</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EUROPRISE European Vaccines and Microbicides Enterprise</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>LSHP-CT-2006-037611</gtr:fundingRef><gtr:id>D7B554C5-0C77-4E07-98EA-A187021FED02</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have discovered that carbopol, a polyanionic carbomer gel, is a highly active systemic adjuvant that primes a strong Th1-type adaptive immune response. This holds promise as a vaccine adjuvant for weakly immunogenic subunit antigens.</gtr:description><gtr:id>E1E84995-7E67-46C0-87D4-04C4CADFDC17</gtr:id><gtr:impact>manuscript submitted for publication</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2009118523</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>carbopol, a potent systemic adjuvant</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>we have discovered a new application for a relatively common chemical, called polyethyleneimine (PEI). We have found that PEI acts as a potent systemic and mucosal adjuvant.</gtr:description><gtr:id>04B094AC-46FF-41FA-B53F-0B10969F0423</gtr:id><gtr:impact>manuscript submitted for publication</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2009297551</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>PEI a novel mucosal adjuvant</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed two new adjuvants that are becoming widely used by research teams internationally for experimental vaccine research in animals, and are currently undergoing preclinical development.</gtr:description><gtr:id>BD666AA5-A916-4836-B1F7-25641FCDBEB7</gtr:id><gtr:impact>collaborations and manuscripts submitted for publication</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>adjuvants</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have established a vaginal immunisation model in both mice and rabbits that allows us to investigate the immunogenicity of antigens alone and in the context of mucosal adjuvants. This model is being used by ourselves and is being adapted for use by our collaborators.</gtr:description><gtr:id>1615E027-4555-418A-9BF8-78588F9D3E8B</gtr:id><gtr:impact>A manuscript submitted for publication</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>vaginal immunisation model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C8A9841-EDCA-49E1-A5CE-061DA8069682"><gtr:id>6C8A9841-EDCA-49E1-A5CE-061DA8069682</gtr:id><gtr:title>Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.</gtr:title><gtr:parentPublicationTitle>Vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a41215f2cd047676351cc10a4a031ae9"><gtr:id>a41215f2cd047676351cc10a4a031ae9</gtr:id><gtr:otherNames>Sattentau QJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2076-393X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/510BA158-2A7A-44CE-A59C-53B87CD4AC20"><gtr:id>510BA158-2A7A-44CE-A59C-53B87CD4AC20</gtr:id><gtr:title>Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6930ae71879c40ce14c54ab812f00c23"><gtr:id>6930ae71879c40ce14c54ab812f00c23</gtr:id><gtr:otherNames>Lai RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2849280B-C3FA-4AA3-9621-8A9286B0FBC7"><gtr:id>2849280B-C3FA-4AA3-9621-8A9286B0FBC7</gtr:id><gtr:title>Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97db9b94079915928b6fa70622564c0d"><gtr:id>97db9b94079915928b6fa70622564c0d</gtr:id><gtr:otherNames>Noti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0AA0A6BD-E15F-4500-9E4D-DA2E1098FA39"><gtr:id>0AA0A6BD-E15F-4500-9E4D-DA2E1098FA39</gtr:id><gtr:title>Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f933dbea8b20f8a0bd3b0c219dee817"><gtr:id>9f933dbea8b20f8a0bd3b0c219dee817</gtr:id><gtr:otherNames>Wegmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25C0DC27-8B2F-4349-AF4B-CAEBF7CE2979"><gtr:id>25C0DC27-8B2F-4349-AF4B-CAEBF7CE2979</gtr:id><gtr:title>Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a923a2486c55aa9fb387c58bb459fe89"><gtr:id>a923a2486c55aa9fb387c58bb459fe89</gtr:id><gtr:otherNames>Smalls-Mantey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/84A10167-6127-4268-8788-13012FBCD342"><gtr:id>84A10167-6127-4268-8788-13012FBCD342</gtr:id><gtr:title>Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a86c7719f926f68edbc10ee0511be54"><gtr:id>4a86c7719f926f68edbc10ee0511be54</gtr:id><gtr:otherNames>Sholukh AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2AA08974-0D4E-4578-841F-34703D75E533"><gtr:id>2AA08974-0D4E-4578-841F-34703D75E533</gtr:id><gtr:title>International network for comparison of HIV neutralization assays: the NeutNet report II.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1602cf654109c7ab23ab2f3f8c16f6cb"><gtr:id>1602cf654109c7ab23ab2f3f8c16f6cb</gtr:id><gtr:otherNames>Heyndrickx L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B68158ED-C56A-48B6-88B6-1F7F30B36EBA"><gtr:id>B68158ED-C56A-48B6-88B6-1F7F30B36EBA</gtr:id><gtr:title>High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/766D39F3-FD5D-4C68-AAA6-0636439035B4"><gtr:id>766D39F3-FD5D-4C68-AAA6-0636439035B4</gtr:id><gtr:title>Vaccinology: A sweet cleft in HIV's armour.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a41215f2cd047676351cc10a4a031ae9"><gtr:id>a41215f2cd047676351cc10a4a031ae9</gtr:id><gtr:otherNames>Sattentau QJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F679622E-3538-4432-AC57-CE550725D62E"><gtr:id>F679622E-3538-4432-AC57-CE550725D62E</gtr:id><gtr:title>Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44f6af75670a188a94192414c08d12f5"><gtr:id>44f6af75670a188a94192414c08d12f5</gtr:id><gtr:otherNames>Sheppard NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC1E0E76-19E6-459C-BA90-122F217D5C0E"><gtr:id>DC1E0E76-19E6-459C-BA90-122F217D5C0E</gtr:id><gtr:title>The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f933dbea8b20f8a0bd3b0c219dee817"><gtr:id>9f933dbea8b20f8a0bd3b0c219dee817</gtr:id><gtr:otherNames>Wegmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC3F1BA9-72FA-4E35-BADA-FE2AC26AF064"><gtr:id>AC3F1BA9-72FA-4E35-BADA-FE2AC26AF064</gtr:id><gtr:title>Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3bb4704dfdf304232ba33945749fa625"><gtr:id>3bb4704dfdf304232ba33945749fa625</gtr:id><gtr:otherNames>Zhou T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/533D3512-6C5A-4403-8B40-EE3680653F24"><gtr:id>533D3512-6C5A-4403-8B40-EE3680653F24</gtr:id><gtr:title>Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f9a50d6c6efaefbdf91e5ad82da1a3b"><gtr:id>8f9a50d6c6efaefbdf91e5ad82da1a3b</gtr:id><gtr:otherNames>Bowles EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29E004B0-D797-4FEC-AB39-E5EAB5BC5A07"><gtr:id>29E004B0-D797-4FEC-AB39-E5EAB5BC5A07</gtr:id><gtr:title>Dry roasting enhances peanut-induced allergic sensitization across mucosal and cutaneous routes in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ef2c0b1ca5456b75d8684c5f992ad47"><gtr:id>5ef2c0b1ca5456b75d8684c5f992ad47</gtr:id><gtr:otherNames>Moghaddam AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A56C7795-59C5-4249-8F11-436DDE430CEC"><gtr:id>A56C7795-59C5-4249-8F11-436DDE430CEC</gtr:id><gtr:title>Development of prophylactic vaccines against HIV-1.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5106E94C-3537-4D40-9CDC-BCCF16345D03"><gtr:id>5106E94C-3537-4D40-9CDC-BCCF16345D03</gtr:id><gtr:title>A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f933dbea8b20f8a0bd3b0c219dee817"><gtr:id>9f933dbea8b20f8a0bd3b0c219dee817</gtr:id><gtr:otherNames>Wegmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4545499-AD18-47C6-AE16-1B25635D4E5B"><gtr:id>A4545499-AD18-47C6-AE16-1B25635D4E5B</gtr:id><gtr:title>Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.</gtr:title><gtr:parentPublicationTitle>Journal of AIDS &amp; clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41dc46d3cf27830c34ab27750cad780e"><gtr:id>41dc46d3cf27830c34ab27750cad780e</gtr:id><gtr:otherNames>Kong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B678572C-E885-4EBF-9BFA-94B56104E3FF"><gtr:id>B678572C-E885-4EBF-9BFA-94B56104E3FF</gtr:id><gtr:title>Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41dc46d3cf27830c34ab27750cad780e"><gtr:id>41dc46d3cf27830c34ab27750cad780e</gtr:id><gtr:otherNames>Kong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AEDA5803-412D-41F5-BDA2-F6606B8AD779"><gtr:id>AEDA5803-412D-41F5-BDA2-F6606B8AD779</gtr:id><gtr:title>EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/313df0512e24e9ea2ef86a625e0742b8"><gtr:id>313df0512e24e9ea2ef86a625e0742b8</gtr:id><gtr:otherNames>Bart PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43FCB67B-B444-4FA8-9A71-9384EA540EE1"><gtr:id>43FCB67B-B444-4FA8-9A71-9384EA540EE1</gtr:id><gtr:title>Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B35330D8-2F2E-4F94-B4CA-B6F405C8F4AC"><gtr:id>B35330D8-2F2E-4F94-B4CA-B6F405C8F4AC</gtr:id><gtr:title>Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ebb3208fe24419dca09846daf2283ec6"><gtr:id>ebb3208fe24419dca09846daf2283ec6</gtr:id><gtr:otherNames>Watkins JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8875D827-C5F0-44BA-B909-4609F2DC97EF"><gtr:id>8875D827-C5F0-44BA-B909-4609F2DC97EF</gtr:id><gtr:title>Immunogen design to focus the B-cell repertoire.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a41215f2cd047676351cc10a4a031ae9"><gtr:id>a41215f2cd047676351cc10a4a031ae9</gtr:id><gtr:otherNames>Sattentau QJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54437C98-C4C9-44F6-B415-3044290DB7A1"><gtr:id>54437C98-C4C9-44F6-B415-3044290DB7A1</gtr:id><gtr:title>Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ef2c0b1ca5456b75d8684c5f992ad47"><gtr:id>5ef2c0b1ca5456b75d8684c5f992ad47</gtr:id><gtr:otherNames>Moghaddam AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CE7C66D-7B89-4E90-AF2B-799F05534E3E"><gtr:id>1CE7C66D-7B89-4E90-AF2B-799F05534E3E</gtr:id><gtr:title>The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b27eb8068840e6b5c8fa150718d02ba1"><gtr:id>b27eb8068840e6b5c8fa150718d02ba1</gtr:id><gtr:otherNames>Kabat AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E12939D-43B3-4DF6-97A8-7DCE5F379569"><gtr:id>8E12939D-43B3-4DF6-97A8-7DCE5F379569</gtr:id><gtr:title>Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/196BAB2C-B20A-44F5-AB63-74B289B5C92D"><gtr:id>196BAB2C-B20A-44F5-AB63-74B289B5C92D</gtr:id><gtr:title>Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08113321f24b6b6673314e0202f493a5"><gtr:id>08113321f24b6b6673314e0202f493a5</gtr:id><gtr:otherNames>Pruzina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54893E57-E8EC-4CF6-85FC-905B6728ADCB"><gtr:id>54893E57-E8EC-4CF6-85FC-905B6728ADCB</gtr:id><gtr:title>Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06bcbe75b239f4826d60252553ba0b23"><gtr:id>06bcbe75b239f4826d60252553ba0b23</gtr:id><gtr:otherNames>Arias MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDD5265F-306A-4368-801C-AD787FAF40EE"><gtr:id>CDD5265F-306A-4368-801C-AD787FAF40EE</gtr:id><gtr:title>Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/809479b55d0feae311ee786e90664f3d"><gtr:id>809479b55d0feae311ee786e90664f3d</gtr:id><gtr:otherNames>Krashias G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/093A03EC-DE53-4124-8520-9205C5661E21"><gtr:id>093A03EC-DE53-4124-8520-9205C5661E21</gtr:id><gtr:title>Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70D3E089-8645-46CE-91A4-AD9DFF52497A"><gtr:id>70D3E089-8645-46CE-91A4-AD9DFF52497A</gtr:id><gtr:title>Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5787684E-07EF-48D9-982C-94252EAEBD72"><gtr:id>5787684E-07EF-48D9-982C-94252EAEBD72</gtr:id><gtr:title>International network for comparison of HIV neutralization assays: the NeutNet report.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/743e34b0b9d126f6857914bd4a540608"><gtr:id>743e34b0b9d126f6857914bd4a540608</gtr:id><gtr:otherNames>Feny? EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/145F4B4B-B810-4D22-9B71-BAE5E67FE391"><gtr:id>145F4B4B-B810-4D22-9B71-BAE5E67FE391</gtr:id><gtr:title>Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8c832858b30de0ee60771b5951953a20"><gtr:id>8c832858b30de0ee60771b5951953a20</gtr:id><gtr:otherNames>Persson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71C4070D-7D3A-4F52-BD1E-A74B18A507F3"><gtr:id>71C4070D-7D3A-4F52-BD1E-A74B18A507F3</gtr:id><gtr:title>Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97db9b94079915928b6fa70622564c0d"><gtr:id>97db9b94079915928b6fa70622564c0d</gtr:id><gtr:otherNames>Noti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E4A8E61-E14E-4243-9BF1-79B997815075"><gtr:id>4E4A8E61-E14E-4243-9BF1-79B997815075</gtr:id><gtr:title>Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens.</gtr:title><gtr:parentPublicationTitle>International immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44f6af75670a188a94192414c08d12f5"><gtr:id>44f6af75670a188a94192414c08d12f5</gtr:id><gtr:otherNames>Sheppard NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0953-8178</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6510AFF-05FE-4FA8-AA43-08F6D1DAFEE6"><gtr:id>D6510AFF-05FE-4FA8-AA43-08F6D1DAFEE6</gtr:id><gtr:title>New templates for HIV-1 antibody-based vaccine design.</gtr:title><gtr:parentPublicationTitle>F1000 biology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a41215f2cd047676351cc10a4a031ae9"><gtr:id>a41215f2cd047676351cc10a4a031ae9</gtr:id><gtr:otherNames>Sattentau QJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1757-594X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09DFA9A7-3199-47C7-B0F4-17FCAA993363"><gtr:id>09DFA9A7-3199-47C7-B0F4-17FCAA993363</gtr:id><gtr:title>A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44f6af75670a188a94192414c08d12f5"><gtr:id>44f6af75670a188a94192414c08d12f5</gtr:id><gtr:otherNames>Sheppard NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C94E1A29-64EB-4030-AA0C-233E0DDC9383"><gtr:id>C94E1A29-64EB-4030-AA0C-233E0DDC9383</gtr:id><gtr:title>Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24e6d62405cd9ed0dccef6bb3a1cbd5d"><gtr:id>24e6d62405cd9ed0dccef6bb3a1cbd5d</gtr:id><gtr:otherNames>Gartlan KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000635</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>